Galapagos N.V.

Galapagos NV is a biotechnology company that develops medicines focused on oncology and immunology, primarily in the United States and Europe. Its pipeline includes GLPG3667, in Phase 2 trials for dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care, in Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma; and GLPG5301, a BCMA CAR-T candidate manufactured at point-of-care, in Phase 1/2 for relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. Incorporated in 1999, it is headquartered in Mechelen, Belgium.